GE HealthCare (GEHC)
NASDAQHealth CareMedical DevicesSnapshot 2026-07-07
$64.89+0.08%
Close 2026-07-07 · 1-day change
Reading GEHC? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track GEHC free→NASDAQHealth CareMedical DevicesSnapshot 2026-07-07
Reading GEHC? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track GEHC free→QuarterlyIQ Insights · GEHC
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 12 valuation methods, at three horizons. Current price $64.89. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $65 GEHC trades at 15× p/e, below its 37× p/e peer median. Our $82 fair value sits well above the price. We hold it with medium confidence: the peer anchor overstates how cheap it looks. Analysts target $65–$90. Not investment advice.
$65.00 – $90.00 (median $80.00) · 9 analysts · as of 2026-06-23
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $4.85/sh owner earnings.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $80.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $39.80 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $29.88 | — | — | Hist. CAGR | high |
| graham number | 12M | $48.48 | — | — | TTM | high |
| Mgmt guidance | 12M | $166.90 | 36.5 | 4.57 | Mgmt | high |
| Peer P/FCF | 12M | $79.69 | 24.0 | 3.33 | TTM | high |
| Peer P/E | 12M | $163.25 | 36.5 | 4.47 | TTM | high |
| Peer P/S | 12M | $127.50 | 2.8 | 45.91 | TTM | high |
| PEG | 12M | $132.72 | 29.7 | 4.47 | TTM | high |
| residual income | 12M | $32.78 | — | — | TTM | high |
| Own P/E history | 12M | $65.76 | 14.7 | 4.47 | TTM | high |
| triangulated | 12M | $167.73 | 36.5 | 4.59 | Triangulated | high |
| Mgmt guidance | 3Y | $241.05 | 36.5 | 6.60 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $68.82 | 24.0 | 2.87 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $213.88 | 36.5 | 5.86 | Analyst | medium |
| Peer P/S | 3Y | $151.34 | 2.8 | 54.49 | Analyst | medium |
| PEG | 3Y | $173.89 | 29.7 | 5.86 | Analyst | medium |
| Own P/E history | 3Y | $86.16 | 14.7 | 5.86 | Analyst | medium |
| Mgmt guidance | 5Y | $308.00 | 36.5 | 8.43 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $62.41 | 24.0 | 2.60 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $239.18 | 36.5 | 6.55 | Analyst | high |
| Peer P/S | 5Y | $169.24 | 2.8 | 60.93 | Analyst | high |
| PEG | 5Y | $194.46 | 29.7 | 6.55 | Analyst | high |
| Own P/E history | 5Y | $96.35 | 14.7 | 6.55 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.